Alcohol Dependence and Harmful Use of Alcohol

Diagnosis and Treatment Options

Anil Batra, Christian A. Müller, Karl Mann, Andreas Heinz

SUMMARY

Background: In Germany today, there are more than 1.8 million persons who are dependent on alcohol, and 1.6 million persons whose use of alcohol is harmful. The many complications of alcohol use are both mental and physical—in particular, gastrointestinal and neurological. Yet more than 80% of persons whose alcohol use is problematic still receive no treatment for their harmful use or dependence, despite contact with the health-care system.

Methods: This article is a selective review of the pertinent literature, including guidelines, meta-analyses, and Cochrane Reviews.

Results: The treatment is divided into an early interventional and motivational phase, qualified withdrawal, long-term cessation therapy, and a stabilization phase. Pharmacotherapy with acamprosate or naltrexone increases the rate of abstinence (number needed to treat: 12 and 20, respectively). If a patient lacks the motivation to abstain from alcohol entirely, reduced consumption can be agreed upon as a goal of treatment. 85% of patients relapse if no further treatment is given after initial detoxification.

Conclusion: What is needed in routine medical practice is practical diagnostic evaluation followed by individually tailored treatment, based on the severity of the condition, the development of the patient’s motivation to be treated, and the local treatment options (e.g., outpatient addiction clinics, counseling centers, or day clinics).

► Cite this as:

German society is permissive with respect to the drinking of alcohol: it is a part of the local culture that is accepted in many different kinds of social events, sometimes even as a ritualized tradition. High per capita alcohol consumption and the early onset of regular or episodic intensive drinking among young people in Germany are the consequence and lead to high alcohol-related morbidity and mortality (e1).

The German S3 treatment guidelines (1) contain a comprehensive set of recommendations for the treatment of alcohol-related disorders. For this review, we searched the literature on the basis of the S3 guidelines, supplemented by the most recent clinical trials and reviews related to the main therapeutic recommendations of the guidelines.

Learning goals

Readers of this article should gain knowledge of

● the impact of alcohol consumption on health,
● strategies for diagnosing and addressing harmful alcohol consumption, and
● measures for the acute and postacute treatment of harmful alcohol use and alcohol dependence.

The epidemiology of alcohol consumption in Germany

Per capita alcohol consumption in Germany has remained for several years at the high level of just under 10 liters of pure ethanol per year (e1). Health-endangering alcohol consumption affects 14% of the adult population aged 19 to 64, or about 7.4 million people. It is estimated that 3.1% of the population meet the diagnostic criteria for harmful alcohol use (4.7% of men and 1.5% of women), while 3.4% of persons aged 19 to 64 (4.8% of men and 2.0% of women; about 1.8
A strong desire or sense of compulsion to take the psychoactive substance (alcohol)

Difficulties in controlling substance-taking behavior in terms of its onset, termination, or levels of use

A physiological withdrawal state when substance use has ceased or been reduced, as evidenced by: the characteristic withdrawal syndrome for the substance; or use of the same (or a closely related) substance with the intention of relieving or avoiding withdrawal symptoms

Evidence of tolerance, such that increased doses of the psychoactive substance are required in order to achieve effects originally produced by lower doses

Progressive neglect of alternative pleasures or interests because of psychoactive substance use

Persistent substance use despite clear evidence of overtly harmful consequences (mental and/or physical)
not merely additive, but in some cases actually multiplicative. About 80% of persons undergoing inpatient treatment who use alcohol regularly also smoke cigarettes every day, and, conversely, persons dependent on cigarette smoking are about twice as likely to develop an alcohol-related disorder as the non-nicotine-dependent general population (8, e6, e7).

**Psychological and neurobiological fundamentals**

Alcohol use is socially accepted and ritualized in Germany. Aside from social reinforcement, the psychotropic effects of alcohol are a further major motivation for its use. Alcohol improves mood in the short term, helps the drinker overcome social anxiety and insecurity, and creates distance to current negative emotions. In the long term, however, the effect of alcohol on the serotonergic and dopaminergic systems increases the risk of a depressive disorder (9, 10).

Like other addicting substances, alcohol causes dopaminergic stimulation in the nucleus accumbens, which rewards alcohol use (9).

Alcohol use is promoted not only by operant conditioning processes, i.e., the pleasant effects of consumption as a reward, but also by classical (Pavlovian) conditioning processes, i.e., the association of previously neutral stimuli in drinking situations with the generation and induction of the desire for alcohol, leading to habitual use. The frequent coupling of alcohol with pleasant situations, mood elevation, disinhibition, and the suppression of negative affects all increase the likelihood of regular drinking.

Alcohol is a drug that directly induces neural adaptation processes which, in turn, partly counteract the effects of alcohol and contribute to the development of tolerance. If the individual then suddenly stops using alcohol, an imbalance arises between the (missing) alcohol-induced sedation and the (persistent) counter-regulatory excitation, leading to withdrawal phenomena. The autonomic manifestations of alcohol in particular—diaphoresis, tremor, tachycardia, hypertension, psychosomatic irritability—may lead the individual to start drinking again, even if he or she would prefer to abstain, and even before the full delirium tremens syndrome arises (e8).

**Box 2**

**The diagnostic criteria for harmful alcohol use, according to the ICD-10 (F10.1) (e9)**

- There is clear evidence that substance use is largely or wholly responsible for mental and/or physical harm, including impaired judgment or abnormal behavior, that can cause impairment or adverse consequences in interpersonal relationships.
- The nature of the harm caused by the substance should be clearly specifiable and describable.
- The pattern of harmful use has been present for at least one month or repeatedly over the past twelve months.
- The diagnostic criteria for another mental or behavioral disorder caused by the same substance are not simultaneously satisfied (with the possible exception of acute intoxication, F10.0).

Problematic alcohol use has a high comorbidity with other types of mental illness, including depressive disorders, anxiety disorders, attention deficit–hyperactivity disorder, and personality disorders that involve emotional instability (dissocial or avoidant personality disorder), as well as alcohol-induced aggressiveness (11, 12).

**Diagnostic classification**

In the International Classification of Diseases (ICD-10) (e9), the harmful use of alcohol (Box 2) and alcohol dependence (Box 1) are coded as F10.1 and F10.2, respectively. The former diagnosis requires the presence of some type of harm consequent to alcohol use, while the latter requires at least three of six criteria for dependence to have been simultaneously met in the past 12 months. The core elements of a diagnosis of dependence are tolerance, desire for alcohol, impaired self-control, and the appearance of withdrawal phenomena.

**International debate on the concept of addiction**

The American Psychiatric Association released the fifth edition of its Diagnostic and Statistical Manual of Psychiatric Diseases (DSM-5) in May 2013 (e10). The category of substance-related disorders was renamed
“addiction and related disorders.” The previous sub-classification of substance-related disorders as abuse, harmful use, or dependence was abandoned in favor of a new, unitary nosological entity (Box 3).

It is not yet clear whether or to what extent this reconceptualization of the concept of addiction will find its way into the upcoming ICD-11. The current subclassification into harmful alcohol use and alcohol dependence will likely be kept. The new DSM-5 concept does have some generally recognized advantages, however; in particular, its dimensional approach accords well with the empirical finding that the criteria for alcohol dependence and abuse lie on a continuum of severity.

The DSM-5 classification has been criticized, however, for softening the diagnosis of alcohol dependence, whose clinical definition was well delimited until now, with the addition of relatively vague criteria for harmful use (e11). For example, repetitive use leading to neglect of responsibilities at work, in school, or at home, repetitive use despite interpersonal problems, and marked expenditure of time in order to obtain alcohol can all be either present or absent in particular cases depending on social norms and prescriptions. In a place where alcohol consumption is generally forbidden, even moderate consumption can become associated with one or more of the above problems and end up merit ing the diagnosis of a substance-related disorder (e11). It is for this reason that some experts advocate the retention of the diagnosis “alcohol dependence.”

Diagnostic testing, laboratory findings, psychometric evaluation instruments, and self-assessment scales

Typical effects of alcohol use that are found on physical examination (polyneuropathy, fetor alcoholicus, rhinophyma, spider nevi, altered facial appearance, and many more) and laboratory biomarkers of alcohol use are clues to the physician that the patient is using alcohol problematically. The most sensitive laboratory test is the gamma-GT concentration; an elevated mean red-cell volume (MCV) is also suggestive but may be

**ICD-10**

In the International Classification of Diseases (ICD-10), alcohol dependence and the harmful use of alcohol are coded separately.

**DSM-5**

In contrast, the American classification system (DSM-5) employs a dimensional concept, according to which alcohol abuse and alcohol dependence belong to the same disease entity.

---

**BOX 3**

**DSM-5 diagnostic criteria for alcohol-related disorder (e10)*

- Alcohol is often taken in larger amounts or for a longer period than was intended.
- There is a persistent desire or unsuccessful efforts to cut down or control alcohol use.
- A great deal of time is spent in activities necessary to obtain alcohol, use alcohol, or recover from its effects.
- Craving, or a strong desire or urge to use alcohol.
- Recurrent alcohol use resulting in a failure to fulfill major role obligations at work, school, or home.
- Continued alcohol use despite persistent or recurrent social or interpersonal problems caused or exacerbated by alcohol.
- Important social, occupational, or recreational activities are given up or reduced because of alcohol use.
- Recurrent alcohol use in situations in which it is physically hazardous.
- Alcohol use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by alcohol.
- Tolerance, i.e., either a need for markedly increased amounts of alcohol to achieve intoxication or desired effect, or else a markedly diminished effect with continued use of the same amount of alcohol.
- Withdrawal, as manifested by either the characteristic withdrawal syndrome for alcohol or by the repeated use of alcohol (or a closely related substance, such as a benzodiazepine) to relieve or avoid withdrawal symptoms.

*(2 or 3 criteria, mild disorder; 4 or 5 criteria, moderate disorder; 6 or more criteria, severe disorder.)
influenced by a nutritional deficiency or other clinical factors. An elevation of the carbohydrate-deficient transferrin (CDT) concentration is correlated with chronic alcohol use; it normalizes within a few weeks if the patient becomes abstinent. GOT and GPT (respectively, ASAT and ALAT) and tests for other substances such as methanol, acetone, or cholesterol ester transfer protein are less specific. For clinical use, gamma-GT, MCV, and CDT are the simplest and most reliable tests. The combined measurement of gamma-GT and CDT seems to be the most sensitive and specific test available (13).

The fact that alcohol has been consumed in the past three to four days can be confirmed by detection of the direct ethanol metabolite ethyl glucuronide (or ethyl sulfate, EtS), which is present for several days in the urine and even longer (up to three months) in hair (14). The sensitivity and specificity of various laboratory tests are shown in the Table.

We recommend the use of objective laboratory tests in combination with screening instruments. Self-administered questionnaires such as AUDIT (the Alcohol Use Disorder Identification Test [e12]) and AUDIT-C (Box 4) (e13, 15) are useful complementary aids to diagnosis, both in the hospital and in general practice.

The diagnosis can only be definitively established by the operationalized clinical criteria of the ICD-10 (Box 1 and 2), of which three out of six must have been simultaneously met in the past 12 months.

### The treatment of alcohol dependence

The treatment of alcohol dependence is divided into an early interventional and motivational phase (in a family-practice setting or an outpatient addiction clinic), acute treatment (detoxification or “qualified withdrawal”), cessation therapy (in a specialized center), and a stabilization phase.

The evidence base for pharmacotherapy now permits robust conclusions to be drawn regarding efficacy (1, 15). The efficacy of motivating techniques, targeted early intervention, and some types of pharmacotherapy is also well documented (1).

Early intervention for counseling and motivating the patient to be treated, primarily through motivational discussion, is often carried out in the primary-care setting or in psychosocial counseling facilities, but can just as well take place (depending on the circumstances) in the workplace, or in relation to other social consequences of alcohol use. The goals of early intervention are to make the patient aware of the alcohol problem and desirous of changing his or her behavior, and to give him or her access to treatment. The most important element is the establishment of an empathetic doctor-patient relationship (16).

Detoxification is carried out in patients suffering from alcohol withdrawal with the objective of preventing the severe manifestations and complications of alcohol withdrawal, including delirium tremens, Wernicke encephalopathy, a grand mal seizure, and central pontine myelinolysis. The risk of complications implies that this should be done in an inpatient setting. When the treatment also includes concomitant motivational psycho-educative measures, it is called “qualified withdrawal”; the duration of treatment is generally three weeks (15). Qualified withdrawal treatment is most commonly administered on a psychiatric inpatient ward or a specialized medical ward for addiction, but it can also be given in an outpatient setting or in a day clinic if severe withdrawal phenomena are not expected to arise.

### Detoxification

Withdrawal seizures and delirium tremens are the most serious manifestations of alcohol withdrawal. Untreated delirium tremens carries a mortality of 5% to 15% (17, 18), and the likelihood of an epileptic seizure during alcohol withdrawal is about 10% (18, 19).

Treatment schemes for withdrawal syndromes involve the initiation of pharmacotherapy with clomethiazole or a benzodiazepine (lorazepam, diazepam, oxazepam, or chlordiazepoxide) in a manner depending on the severity

### Psychometric evaluation instruments

Further aids to diagnosis, aside from the diagnostic criteria of the ICD-10, include psychometric self-assessment instruments (AUDIT, AUDIT-C) and alcohol-specific laboratory tests (GGT, MCV, CDT and EtG).

<table>
<thead>
<tr>
<th>Marker</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOT</td>
<td>15–69%</td>
<td>low</td>
</tr>
<tr>
<td>GPT</td>
<td>18–58%</td>
<td>low</td>
</tr>
<tr>
<td>Gamma-GT</td>
<td>34–85%</td>
<td>11–95%</td>
</tr>
<tr>
<td>CDT</td>
<td>39–94%</td>
<td>82–100%</td>
</tr>
<tr>
<td>MCV</td>
<td>34–89%</td>
<td>26–95%</td>
</tr>
</tbody>
</table>

### Qualified withdrawal treatment

Qualified withdrawal consists of psycho-educative measures to promote insight into the condition, motivational interventions, and, if needed, medical treatment of the alcohol withdrawal syndrome.
of the withdrawal phenomena (19, 20); in general, the doses of these drugs can then be reduced over 7 days. Benzodiazepines should be given in 2 to 4 doses per day; clomethiazole should be given at closely spaced intervals (every 2 hours) because of its short half-life. Carbamazepine and oxcarbazepine can alternatively be used to treat alcohol withdrawal syndrome (1, 15).

The elements of qualified withdrawal
Qualified withdrawal involves not only preventing the serious complications of alcohol withdrawal but also motivating the patient for stable, long-term abstinence, with therapeutic support if necessary and with integration into the German nationwide addiction aid and self-help system.

Psycho-education mainly consists of informing the patient about the conditions that promote alcohol dependence and enabling him or her to consider rationally the advantages and disadvantages of abstinence, as opposed to continued alcohol use, with the aid of motivational discussion techniques (e14). This can be enhanced by the integration of family members and the addition of elements from social competence training, relaxation therapy, ergotherapy, and physiotherapy.

After detoxification
About 85% of alcohol-dependent patients who undergo detoxification without any further treatment suffer a relapse (21, 22). The main goal of postacute treatment is to increase the chance of long-term abstinence. Short-term detoxification makes sense only if followed by postacute treatment, which can be delivered in an outpatient or day-clinic setting or on an addiction-specific inpatient rehabilitation ward. The treatment generally consists of psychotherapy (often behavior therapy), including elements of social competence training, stress management training, stimulus exposure techniques, relapse prevention, and relapse management, as well as the reinforcement of self-control, re-establishment of social resources, occupational measures, and job searching to promote personal participation. The behavior-therapeutic techniques developed in the 1970s for alcohol-specific psychotherapy have been extended and supplemented in recent years with cognitive behavioral elements (22). The efficacy of individual methods is well established, particularly motivational training, cognitive behavior-therapeutic training, abstinence training, social competence training, exposure techniques, and community-based reinforcement models.

There have not, however, been any reported clinical trials of the common type of postacute treatment (22). These patients’ rehabilitation, post-rehabilitative care, and reintegration into the workplace and into a stable familial and social environment should always be accompanied by participation in a self-help group and continuing care by the family physician, with regular abstinence checks, updating of coping skills for problematic situations, and effective relapse management (1, 22).

The long-term pharmacotherapy of alcohol dependence
So-called anti-craving drugs can support abstinence. They must be integrated into an overall treatment plan as a complement to other, behavioral strategies to treat

Detoxification
Withdrawal seizures and delirium tremens are the most serious complications of alcohol withdrawal.

The need for further treatment
About 85% of alcohol-dependent patients who undergo detoxification without any further treatment suffer a relapse.
addition. The needed motivational support can be provided in regularly occurring discussions in an outpatient addiction clinic or in the general practitioner’s office.

The approved drugs of this type in Germany are acamprosate and naltrexone, an opioid antagonist. Meta-analyses have shown both to be effective for relapse prevention (23, 24), with a number needed to treat (NNT) of about 12 and about 20, respectively (25, 26).

Disulfiram was once used in Germany for aversive therapy but is no longer approved and has become practically unavailable. Nonetheless, the efficacy of aversive therapy with disulfiram is well documented, above all in combination with frequent psychotherapy (27–29). The mechanism of action of disulfiram is the irreversible inhibition of aldehyde dehydrogenase, leading to the accumulation of toxic acetaldehyde and, in turn, to facial erythema, tachycardia, urinary urgency, nausea, and headache whenever the patient drinks alcohol.

A further substance that has not yet been approved for this indication is baclofen, a GABAß agonist (30). It can only be used off label at present.

**Reduced drinking: pro and con**

Reduced drinking as a strategy (previously known as “controlled drinking”) remains a highly contentious matter (31, e15, e16).

Multiple studies (32, 33, e17) have shown that reduced drinking is a feasible goal, at least when the patient is in the early phase of dependence and has only a small number of alcohol-related problems. Patients treated with this goal in mind were able to achieve stable drinking patterns for 6 or 12 months (depending on the study). There is, however, no way to determine what percentage of patients might continue to be stably reduced drinkers over the long term after such treatment, because the studies generally yielded no information about outcomes beyond the mid-range follow-up interval in the groups of patients who reduced their drinking, became abstinent, or kept on drinking as before (34). In any case, 10–30% of patients achieve abstinence during or after participation in a drinking reduction program (e15).

A few studies (35) have shown that drinking reduction works, but that patients whose goal it is to quit drinking achieve better results than those whose goal is merely to drink less—better results, that is, with respect to both abstinence and reduced drinking. On the other hand, certain groups of patients are often left out of consideration when the results of abstinence-oriented programs are evaluated, including those who engage in risky alcohol use, those who are severely dependent and drink constantly, and homeless alcoholics. There are some studies aiming to show that managed access to alcohol as a means of damage control for chronically homeless alcohol-dependent persons can improve their quality of life and lessen uncontrolled drinking behavior (36, 37). Moreover, the reduction of daily alcohol intake often enables patients to reach an agreement with their therapists on new treatment goals (38). Reduced-drinking programs include not only pharmacological support, but also behaviorally oriented recommendations on how to deal with alcohol use or the desire to drink (36). Nonetheless, despite the documented advantages of the reduced-drinking approach, one must take care, when implementing it in practice, not to offer it as an alternative to abstinence for patients who are likely to benefit from abstinence therapy, which current evidence supports as the safest, most effective form of treatment. Possible indications for reduced drinking as a treatment goal include harmful alcohol use without dependence, a lack of motivation for abstinence, or multiple, failed professionally supported attempts at abstinence and a lack of motivation to make a further attempt.

There has been renewed discussion of the possibility of stably reducing alcohol consumption without eliminating it since the recent demonstration that nalmefen, an opioid modulator (µ- and δ-receptor agonist and partial κ-receptor agonist), is effective for this purpose. Three recent studies and an earlier one from Finland have shown that even the groups treated with counseling and placebo were able to lessen the amount they drank by about 60% for six and twelve months, with a moderate and significant additional effect for nalmefen (39). The advocates of the reduced-drinking approach saw this as strong empiric support for their concept. It should be emphasized, however, that this type of treatment is restricted to persons without any known physical manifestations of alcohol withdrawal who do not require immediate detoxification. Nalmefen should only be given in combination with psychosocial support. Moreover, the treatment should only be started in persons whose alcohol consumption is still at a high-risk level 14 days after initial examination. Nalmefen can only be prescribed for three months, or, in justified exceptional cases, for six months at most. According to the German Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA), nalmefen confers no additional benefit beyond naltrexone for the same indications (40).
Conformity with guidelines

The current S3 guidelines for the treatment of alcohol and tobacco dependence were published and released on the Internet on 30 January 2015 (1, 15). They contain treatment recommendations accompanied by extensive explanatory text and supported by references to the literature.

Conflict of interest statement

Prof. Batra has received third-party funding from Alkermes for participating in a multicenter trial.

Dr. Müller has received research support and payment for preparing scientific meetings from Lundbeck.

Prof. Mann has served as a paid consultant for Lundbeck, from which he has also received reimbursement of meeting participation fees, travel and accommodation expenses, payment for preparing continuing medical education events and for authorship of a publication with a topic related to that of this article, and financial support for a research project that he initiated.

Prof. Heinz states that he has no conflict of interest.

Manuscript submitted on 23 June 2015, revised version accepted on 9 March 2016.

Translated from the original German by Ethan Taub, M.D.

REFERENCES


Stably reduced drinking

Renewed discussion of the stabe reduction (but not elimination) of alcohol consumption has followed the recent demonstration that nalmefen, an opioid modulator, is effective for this purpose.


Further information on CME

This article has been certified by the North Rhine Academy for Postgraduate and Continuing Medical Education. Deutsches Ärzteblatt provides certified continuing medical education (CME) in accordance with the requirements of the Medical Associations of the German federal states (Länder). CME points of the Medical Associations can be acquired only through the Internet, not by mail or fax, by the use of the German version of the CME questionnaire. See the following website: cme.aerzteblatt.de.

Participants in the CME program can manage their CME points with their 15-digit “uniform CME number” (einheitliche Fortbildungsnummer, EFN). The EFN must be entered in the appropriate field in the cme.aerzteblatt.de website under "meine Daten" ("my data"), or upon registration. The EFN appears on each participant’s CME certificate.

This CME unit can be accessed until 24 July 2016, and earlier CME units until the dates indicated:

“Acute Low Back Pain” (issue 13/2016) until 26 June 2016;

“The Evidence-Based Treatment of Inguinal Hernia” (issue 9/2016) until 29 May 2016;

“Chronic Inflammatory Bowel Diseases” (issue 5/2016) until 1 May 2016.
Please answer the following questions to participate in our certified Continuing Medical Education program. Only one answer is possible per question. Please select the most appropriate answer.

**Question 1**
How many adults in Germany meet the diagnostic criteria for alcohol dependence?
- a) 0.8 million
- b) 1.8 million
- c) 2.8 million
- d) 3.8 million
- e) 4.8 million

**Question 2**
What combination of laboratory tests seems to be most sensitive and specific for chronic alcohol use?
- a) Blood gas analysis and creatinine kinase concentration
- b) Carbon monoxide concentration in exhaled air and fasting blood sugar
- c) Red blood cell concentration and urinary urea concentration
- d) Methanol and acetone concentrations
- e) Gamma-GT and carbohydrate-deficient transferrin concentrations

**Question 3**
What drugs are approved in Germany for the purpose of keeping alcohol-dependent patients abstinent?
- a) Acamprosate and naltrexone
- b) Nalmefen and baclofen
- c) Clomethiazol and disulfiram
- d) Lorazepam and diazepam
- e) Oxazepam and chlordiazepoxide

**Question 4**
Which of the following is a recommended element of qualified detoxification?
- a) Fasting
- b) Psychotherapy based on depth psychology
- c) Motivational discussions
- d) Creative therapy
- e) Biographical history

**Question 5**
Which of the following is included in the DSM-5 as one of the 11 diagnostic criteria for an alcohol-related disorder?
- a) The diagnostic criteria for another mental or behavioral disorder caused by the same substance are not simultaneously satisfied.
- b) Craving, i.e., a strong desire for alcohol, is present.
- c) Excessive alcohol use has been present for at least one month or repeatedly over the past year.
- d) Abnormal behavior is present that can lead to impairment or negative consequences in interpersonal relationships.
- e) Clear evidence indicates that substance use is responsible for the disorder.

**Question 6**
What is the neuropsychological explanation for the development of alcohol dependency?
- a) Like other addictive substances, alcohol promotes the release of dopamine in the brain’s “reward system” (including the nucleus accumbens); this, in turn, rewards alcohol consumption, in a vicious cycle.
- b) Chronic alcohol use lessens the sensitivity of GABA<sub>e</sub> receptors.
- c) Because of a genetic difference in persons prone to alcoholism, there is an increased neuronal calcium inflow through the open ion channels of NMDA receptors.
- d) Increased histone modification in the DRD3 genes of the striatum leads to chronification of the disorder.
- e) Alcohol promotes the expression of acetylcholine receptors, leading to tolerance.

**Question 7**
What are the most serious complications of alcohol withdrawal?
- a) Seizures and delirium tremens
- b) Tremor and hyperhidrosis
- c) Insomnia and restless legs syndrome
- d) Pruritus and ulceration
- e) Sleep apnea and visual loss

**Question 8**
What percentage of alcohol-dependent patients relapse if given no further treatment beyond detoxification?
- a) 55%
- b) 65%
- c) 75%
- d) 85%
- e) 95%

**Question 9**
Which of the following may be an indication for “reduced drinking”?
- a) Harmful alcohol use with demonstrated dependence
- b) Multiple failed professionally supported attempts to abstain
- c) High motivation for abstinence
- d) Stable social predictors
- e) Lack of a self-help group nearby

**Question 10**
What is the approximate per capita consumption of pure alcohol in Germany?
- a) 6 L/year
- b) 8 L/year
- c) 10 L/year
- d) 12 L/year
- e) 14 L/year
Additional material to:

Alcohol Dependence and Harmful Use of Alcohol
Diagnosis and Treatment Options

by Anil Batra, Christian A. Müller, Karl Mann, and Andreas Heinz


eREFERENCES